Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 9/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.53 |
| ▸ | TFPI | P10646 | 1/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.52 |
| ▸ | NPY1R | P25929 | 2/20 | 0.52 |
| ▸ | NPY4R | P50391 | 2/20 | 0.52 |
| ▸ | BACE1 | P56817 | 2/20 | 0.52 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.52 |
| ▸ | APC | P25054 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31614444 | 0.98 | OPRD1 (0.56) | OPRD1OPRM1OPRK1TFPINPY5R | |
| SCHEMBL31614415 | 0.98 | OPRD1 (0.55) | OPRD1OPRM1OPRK1TFPINPY5R | |
| SCHEMBL31614432 | 0.94 | OPRD1 (0.56) | OPRD1OPRM1OPRK1NPY5RNPY1R | |
| SCHEMBL29375967 | 0.92 | TFPI (0.59) | OPRD1OPRM1OPRK1TFPINPY1R | |
| SCHEMBL31614425 | 0.92 | OPRD1 (0.56) | OPRD1OPRM1OPRK1NPY1RNPY4R | |
| SCHEMBL30721576 | 0.91 | TFPI (0.61) | OPRD1OPRM1OPRK1TFPI | |
| SCHEMBL30612509 | 0.90 | OPRM1 (0.59) | OPRD1OPRM1OPRK1TFPIBACE1 | |
| SCHEMBL29525489 | 0.89 | TFPI (0.63) | OPRD1OPRM1OPRK1TFPI | |
| SCHEMBL31614421 | 0.87 | OPRD1 (0.57) | OPRD1OPRM1OPRK1NPY1RNPY4R | |
| SCHEMBL30473779 | 0.87 | NPY4R (0.60) | NPY5RNPY1RNPY4RBACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264809-A1 | CHEMICALLY MODIFIED PEPTIDES AND USE THEREOF | NEUROCRINE BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250188115-A1 | PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2025-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188115-A1 | PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE | GLP1R, IAPP, GCG | OPRD1 4401/4885OPRM1 4237/4885OPRK1 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.